Scynexis price to sales ratio SCYX

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: 2.0×
9-year median: 10.4×
Against its 9-year history: 18th; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.4× to 198×
Peer median: 0.4×

Scynexis' price to sales ratio is 2.0× as of Oct 23, 2026.

That is below its 9-year median of 10.4×, lower than on 82% of days in the last 9 years.

Over that time it ranged from 0.4× in Mar 2024 to 198× in Oct 2017.

The median for 4 large drugmakers of a similar size is 0.4×.

Price to sales ratio over time

median 10.4×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.0×	1.7×	11.8×
2025	8.4×	4.3×	14.4×
2024	4.4×	0.4×	6.9×
2023	0.6×	0.4×	22.7×
2022	12.2×	4.9×	51.9×
2021	11.6×	9.7×	16.4×
2020	n/m a value too high to mean anything
2019	138×	115×	139×
2018	99.1×	71.8×	197×
2017	196×	161×	198×
2016	198×	6.9×	198×
2015	9.9×	4.0×	11.1×

Against its peers

Companies in Drug Manufacturers - General nearest Scynexis' size, closest first, today.

Company	Price to sales ratio
SCYXScynexis	2.0×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

Where Scynexis ranks

#38of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Scynexis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.